Tofacitinib Shows Promising Results in Phase III Trial for Ankylosing Spondylitis Treatment
• A phase III clinical trial demonstrated that tofacitinib, an oral JAK inhibitor, significantly improved symptoms in patients with active ankylosing spondylitis who had inadequate response to NSAIDs.
• The study showed rapid and sustained clinical responses with tofacitinib 5mg twice daily, meeting both primary and key secondary endpoints for disease improvement measures.
• The safety profile was consistent with tofacitinib's established record in other conditions, with no new safety concerns identified during the 48-week study period.
© Copyright 2025. All Rights Reserved by MedPath